VisionSort: Applications in Stem Cell R&D Webinar

Learn more about VisionSort applications in stem cell R&D and regenerative medicine. Highlights include applications in induced pluripotent stem cells (iPSC), human mesenchymal stem cells (hMSC), and progenitor cells. Combining gentle microfluidics based sorting that maintains stem cell viability and differentiation potential with sensitive, label-free isolation of specific cell phenotypes, VisionSort is uniquely positioned to address fundamental challenges in stem cell R&D and regenerative medicine.  

VisionSort for Phenotypic Drug Screening

Learn more about VisionSort applications in phenotypic drug screening. Providing a perfect complement to existing drug discovery technologies, see how the power of AI and high-resolution morphological profiling come together to enable new phenotypes to screen for and the identification of differentiated hits for discovery campaigns.

Label-Free High Throughput CRISPR-Based Screening for Morphological Phenotypes in Flow

The development of CRISPR-Cas9 genome editing technology has led to the emergence of a new generation of novel life sciences applications. In drug discovery, researchers have harnessed the precision of selective gene knockouts by CRISPR to enable genome-wide drug screening. By mapping genotypes to phenotypes, CRISPR-based phenotypic screens can enable a better understanding of drug mechanism of actions (MOAs) and identification of novel druggable targets. However, current phenotypic CRISPR screening approaches rely heavily on microscopic imaging of target phenotypes, a process that imposes throughput limitations and restricts screening to only a handful of simple phenotypes based on binary fluorescence signals. To fully realize the potential of CRISPRbased phenotypic screening, here […]

High Throughput CRISPR-Based Phenotypic Screening in Flow for Complex Intracellular Phenotypes

The development of CRISPR-Cas9 genome editing technology has led to the emergence of a new generation of novel life sciences applications1. In drug discovery, researchers have harnessed the precision of selective gene knockouts by CRISPR to enable genome-wide drug screening. By mapping genotypes to phenotypes, CRISPR-based phenotypic screens can enable a better understanding of drug mechanism of actions (MOAs) and identification of novel druggable targets. However, current phenotypic CRISPR screening approaches rely heavily on microscopic imaging of target phenotypes, a process that imposes throughput limitations and restricts screening to only a handful of simple phenotypes by binary fluorescence signals. To fully realize the potential of CRISPR-based phenotypic screening, here show […]